Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 02 2024 - 7:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing
company, today announced that it will host a conference call and
webcast on Wednesday, May 8, 2024, at 8:00 a.m.
ET to discuss results for the first quarter 2024 and to
provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-877-407-0989 and international
callers should dial +1-201-389-0921 approximately five minutes
before the call begins.
- Participants should ask to be connected to the Editas Medicine
Earnings Conference Call.
The conference call will also be webcast and can be accessed
from the “Investors” section of the Editas Medicine website at
https://www.editasmedicine.com. A replay will be available at the
same site approximately one hour after the completion of the
call.
In addition to the conference call, management will participate
in the following upcoming investor conferences:
- Bank of America Health Care Conference
2024Date: Tuesday, May 14Location: Las Vegas, NV
- 2024 RBC Capital Markets Global Healthcare
Conference Format: Fireside ChatDate: Wednesday, May
15Time: 2:05 p.m. ETLocation: New York, NY
- Stifel’s 2nd Annual Genetic Medicines
ForumDate: Tuesday, May 28Location: Virtual
The fireside chat at RBC Capital Markets will be webcast and can
be accessed from the “Investors” section of the Company’s website
at www.editasmedicine.com. An archived replay will be available for
approximately 30 days following each event.
About Editas MedicineAs a
clinical-stage gene editing company, Editas Medicine is focused on
translating the power and potential of the CRISPR/Cas12a and
CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute’s Cas12a patent estate and Broad
Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024